Yu Chen

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Development of a second-generation antiandrogen for treatment of advanced prostate cancer
    Chris Tran
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 324:787-90. 2009
  2. ncbi Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
    Yu Chen
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lancet Oncol 10:981-91. 2009
  3. ncbi Targeting the androgen receptor pathway in prostate cancer
    Yu Chen
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Curr Opin Pharmacol 8:440-8. 2008
  4. ncbi ARN-509: a novel antiandrogen for prostate cancer treatment
    Nicola J Clegg
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Res 72:1494-503. 2012
  5. ncbi Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer
    Brett S Carver
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Cell 19:575-86. 2011
  6. ncbi ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours
    Ping Chi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 467:849-53. 2010
  7. ncbi Prostate cancer in 2011: Hitting old targets better and identifying new targets
    Yu Chen
    Human Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Nat Rev Clin Oncol 9:70-2. 2012
  8. ncbi Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers
    Yu Chen
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Cell 17:415-6. 2010
  9. ncbi In vivo analysis of human multidrug resistance protein 1 (MRP1) activity using transient expression of fluorescently tagged MRP1
    Asha Rajagopal
    Laboratory of Cellular Biophysics, The Rockefeller University, New York, New York 10021, USA
    Cancer Res 62:391-6. 2002

Collaborators

Detail Information

Publications9

  1. ncbi Development of a second-generation antiandrogen for treatment of advanced prostate cancer
    Chris Tran
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 324:787-90. 2009
    ..These compounds thus appear to be promising candidates for treatment of advanced prostate cancer...
  2. ncbi Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
    Yu Chen
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lancet Oncol 10:981-91. 2009
    ..Both agents are undergoing phase 3 testing. Here, we review the basic science and clinical development of these and other agents...
  3. ncbi Targeting the androgen receptor pathway in prostate cancer
    Yu Chen
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Curr Opin Pharmacol 8:440-8. 2008
    ..Many of these strategies are currently being tested in clinical trials in CRPC...
  4. ncbi ARN-509: a novel antiandrogen for prostate cancer treatment
    Nicola J Clegg
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Res 72:1494-503. 2012
    ..Our findings offer preclinical proof of principle for ARN-509 as a promising therapeutic in both castration-sensitive and castration-resistant forms of prostate cancer...
  5. ncbi Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer
    Brett S Carver
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Cell 19:575-86. 2011
    ....
  6. ncbi ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours
    Ping Chi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 467:849-53. 2010
    ..It also represents a novel mechanism of oncogenic transcription factor activation...
  7. ncbi Prostate cancer in 2011: Hitting old targets better and identifying new targets
    Yu Chen
    Human Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Nat Rev Clin Oncol 9:70-2. 2012
    ..These outcomes contrasted with the heightened controversy generated by the recommendation against PSA screening and other early detection strategies...
  8. ncbi Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers
    Yu Chen
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Cell 17:415-6. 2010
    ..There is an extraordinary degree of overlap between binding sites, with the suggestion that ERG inhibits androgen receptor-mediated differentiation and promotes EZH2-mediated dedifferentiation...
  9. ncbi In vivo analysis of human multidrug resistance protein 1 (MRP1) activity using transient expression of fluorescently tagged MRP1
    Asha Rajagopal
    Laboratory of Cellular Biophysics, The Rockefeller University, New York, New York 10021, USA
    Cancer Res 62:391-6. 2002
    ..Additionally, MRP1-EGFP expression protected cells from the microtubule depolymerization caused by vincristine and colchicine, but not by vinblastine...